Literature DB >> 6285736

Mechanism of action and selectivity of acyclovir.

G B Elion.   

Abstract

Acyclovir, an acrylic purine nucleoside analog, is a highly potent inhibitor of herpes simplex virus (HSV), types 1 and 2, and varicella zoster virus, and has extremely low toxicity for the normal host cells. This selectivity is due to the ability of these viruses to code for a viral thymidine kinase capable of phosphorylating acyclovir to a monophosphate; this capability is essentially absent in uninfected cells. The acyclovir monophosphate (acyclo-GMP) is subsequently converted to acyclovir triphosphate (acyclo-GTP) by cellular enzymes. Acyclo-GTP persists in HSV-infected cells for many hours after acyclovir is removed from the medium. The amounts of acyclo-GTP formed in HSV-infected cells are 40 to 100 times greater than in uninfected Vero cells. Acyclo-GTP acts as a more potent inhibitor of the viral DNA polymerases than of the cellular polymerases. The DNA polymerases of HSV-1 and HSV-2 also use acyclo-GTP as a substrate and incorporate acyclo-GMP into the DNA primer-template to a much greater extent than do the cellular enzymes. The viral DNA polymerase binds strongly to the acyclo-GMP-terminated template, and in thereby inactivated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285736     DOI: 10.1016/0002-9343(82)90055-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  75 in total

Review 1.  Progress in the development of new therapies for herpesvirus infections.

Authors:  Nathan B Price; Mark N Prichard
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

Review 2.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

3.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

Review 4.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Acyclovir-induced thrombocytopaenia in a patient with SLE.

Authors:  Irene Tsappa; Constantinos Missouris; Savvas Psarellis
Journal:  BMJ Case Rep       Date:  2018-06-08

6.  Acyclovir therapy for chickenpox in children with hematological malignancies.

Authors:  J Bogusławska-Jaworska; E Kościelniak; B Rodziewicz
Journal:  Eur J Pediatr       Date:  1984-06       Impact factor: 3.183

7.  Wild Type p53 gene sensitizes rat C6 glioma cells to HSV-TK/ACV treatment in vitro and in vivo.

Authors:  Qiang Huang; Zhibo Xia; Yongping You; Peiyu Pu
Journal:  Pathol Oncol Res       Date:  2010-01-19       Impact factor: 3.201

8.  The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.

Authors:  E A Gustafson; A C Chillemi; D R Sage; J D Fingeroth
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Dichotomy of glycoprotein g gene in herpes simplex virus type 1 isolates.

Authors:  Elham Rekabdar; Petra Tunbäck; Jan-Ake Liljeqvist; Magnus Lindh; Tomas Bergström
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: Four approved indications and 13 off-label uses.

Authors:  Fred Y Aoki
Journal:  Can J Infect Dis       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.